Europe Antibody Drug Conjugates Market Size Report to 2028

Europe Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application (Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others), By Technology, By Country and Growth Forecast, 2022 - 2028

Published Date: May-2022 | Number of Pages: 91 | Format: PDF | Report ID: KBV-18017

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Antibody Drug Conjugates Market, by Application
1.4.2 Europe Antibody Drug Conjugates Market, by Technology
1.4.3 Europe Antibody Drug Conjugates Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition & mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May – 2022, Mar) Leading Players

Chapter 4. Europe Antibody Drug Conjugates Market by Application
4.1 Europe Breast Cancer Market by Country
4.2 Europe Blood Cancer Market by Country
4.3 Europe Urothelial Cancer & Bladder Cancer Market by Country
4.4 Europe Others Market by Country

Chapter 5. Europe Antibody Drug Conjugates Market by Technology
5.1 Europe Cleavable Linker Market by Country
5.2 Europe Non-Cleavable Linker Market by Country
5.3 Europe Others Market by Country

Chapter 6. Europe Antibody Drug Conjugates Market by Country
6.1 Germany Antibody Drug Conjugates Market
6.1.1 Germany Antibody Drug Conjugates Market by Application
6.1.2 Germany Antibody Drug Conjugates Market by Technology
6.2 UK Antibody Drug Conjugates Market
6.2.1 UK Antibody Drug Conjugates Market by Application
6.2.2 UK Antibody Drug Conjugates Market by Technology
6.3 France Antibody Drug Conjugates Market
6.3.1 France Antibody Drug Conjugates Market by Application
6.3.2 France Antibody Drug Conjugates Market by Technology
6.4 Russia Antibody Drug Conjugates Market
6.4.1 Russia Antibody Drug Conjugates Market by Application
6.4.2 Russia Antibody Drug Conjugates Market by Technology
6.5 Spain Antibody Drug Conjugates Market
6.5.1 Spain Antibody Drug Conjugates Market by Application
6.5.2 Spain Antibody Drug Conjugates Market by Technology
6.6 Italy Antibody Drug Conjugates Market
6.6.1 Italy Antibody Drug Conjugates Market by Application
6.6.2 Italy Antibody Drug Conjugates Market by Technology
6.7 Rest of Europe Antibody Drug Conjugates Market
6.7.1 Rest of Europe Antibody Drug Conjugates Market by Application
6.7.2 Rest of Europe Antibody Drug Conjugates Market by Technology

Chapter 7. Company Profiles
7.1 Takeda Pharmaceutical Company Limited
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expense
7.1.1 Recent strategies and developments:
7.1.1.1 Partnerships, Collaborations, and Agreements:
7.1.1.2 Acquisitions and Mergers:
7.2 F. Hoffmann-La Roche Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 AstraZeneca PLC
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 GlaxoSmithKline PLC
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations and Agreements:
7.6 Astellas Pharma, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.6.5.2 Approvals and Trials:
7.7 Gilead Sciences, Inc.
7.7.1 Company overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.7.4 Recent strategies and developments:
7.7.4.1 Acquisitions and Mergers:
7.7.4.2 Partnerships, Collaborations and Agreements:
7.8 Seagen, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expenses
7.8.4 Recent strategies and developments:
7.8.4.1 Partnerships, Collaborations, and Agreements:
7.9 ADC Therapeutics SA
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expenses
7.9.4 Recent strategies and developments:
7.9.4.1 Partnerships, Collaborations, and Agreements:
7.9.4.2 Approvals and Trials:
7.10. Daiichi Sankyo Company, Limited
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Research & Development Expense
7.10.4 Recent strategies and developments:
7.10.4.1 Partnerships, Collaborations, and Agreements:

Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities